Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scinopharm Taiwan's EPS (Basic) for the
three
months ended in Jun. 2026 was NT$-0.04.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0.05.
During the past 12 months, Scinopharm Taiwan's average EPS without NRIGrowth Rate was -72.70% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -27.70% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -8.20% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was -10.20% per year.
During the past 13 years, Scinopharm Taiwan's highest 3-Year average EPS without NRI Growth Rate was 18.60% per year. The lowest was -31.20% per year. And the median was -11.60% per year.
Scinopharm Taiwan (TPE:1789) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Scinopharm Taiwan Earnings per Share (Diluted) Related Terms
Scinopharm Taiwan Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan Earnings per Share (Diluted) Chart
TPE:1789 vs ZTS: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's PE Ratio distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's PE Ratio falls into.
Scinopharm Taiwan Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Scinopharm Taiwan's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of NT$0.05 mean?
Scinopharm Taiwan (TPE:1789) has a Earnings per Share (Diluted) of NT$0.05 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Scinopharm Taiwan and its competitors. According to the industry distribution chart, Scinopharm Taiwan ranks #702 out of 785 companies in the Drug Manufacturers industry, placing it in the top 89.4%.
Is Scinopharm Taiwan's Earnings per Share (Diluted) too high?
Scinopharm Taiwan's current Earnings per Share (Diluted) is NT$0.05. Based on the distribution chart, Scinopharm Taiwan ranks #702 out of 785 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Scinopharm Taiwan has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Earnings per Share (Diluted) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #702 out of 785 companies for Earnings per Share (Diluted). This places Scinopharm Taiwan in the lower half of its industry. The industry median Earnings per Share (Diluted) is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.60, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Scinopharm Taiwan and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current Earnings per Share (Diluted) is NT$0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Fairly Valued. The stock's GF Value™ is NT$20.96, compared to a current price of NT$19.15 — trading 8.6% below its estimated fair value. The current Earnings per Share (Diluted) is NT$0.05. Scinopharm Taiwan's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Earnings per Share (Diluted) is NT$0.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$19.15 is trading 8.6% below its estimated GF Value™ of NT$20.96.
GuruFocus considers Scinopharm Taiwan to be Fairly Valued.
Key valuation signals for TPE:1789:
Earnings per Share (Diluted): NT$0.05
GF Value™: NT$20.96 vs. price of NT$19.15 (8.6% below fair value)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
70GF Score
Get the complete analysis for TPE:1789
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
